Xencor’s stock surged after securing a proffered paper oral slot at ESMO 2026 for its Phase 1 renal cell carcinoma study.
Xencor (XNCR) shares climbed 17% Friday, closing at $17.47 after gaining $2.52. The rally followed the company’s announcement of a proffered paper oral presentation at ESMO 2026 for its Phase 1 trial of XmAb819 in advanced clear cell renal cell carcinoma.
The presentation slot highlights progress in Xencor’s oncology pipeline, a key focus for investors. Prior updates on XmAb819 had drawn limited market reaction, but the ESMO 2026 inclusion signals heightened visibility for the asset.
No immediate market reaction beyond the stock price movement was reported.